Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
VSTM 
Verastem Inc (VSTM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: VSTM (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
9 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $15.25
1 Year Target Price $15.25
| 7 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -79.37% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 228.04M USD | Price to earnings Ratio - | 1Y Target Price 15.25 |
Price to earnings Ratio - | 1Y Target Price 15.25 | ||
Volume (30-day avg) 9 | Beta 0.85 | 52 Weeks Range 2.10 - 9.10 | Updated Date 06/30/2025 |
52 Weeks Range 2.10 - 9.10 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.36 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1310.71% |
Management Effectiveness
Return on Assets (TTM) -64.19% | Return on Equity (TTM) -2159.52% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 187265055 | Price to Sales(TTM) 22.8 |
Enterprise Value 187265055 | Price to Sales(TTM) 22.8 | ||
Enterprise Value to Revenue 18.73 | Enterprise Value to EBITDA -0.19 | Shares Outstanding 54949200 | Shares Floating 42650996 |
Shares Outstanding 54949200 | Shares Floating 42650996 | ||
Percent Insiders 0.92 | Percent Institutions 78.87 |
Analyst Ratings
Rating 3 | Target Price 15.25 | Buy 2 | Strong Buy 7 |
Buy 2 | Strong Buy 7 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Verastem Inc
Company Overview
History and Background
Verastem, Inc. is a biopharmaceutical company committed to advancing new medicines for patients with cancer. Founded in 2010, the company focuses on developing and commercializing therapies that improve outcomes for cancer patients.
Core Business Areas
- Oncology Drug Development: Verastem focuses on developing and commercializing new medicines for cancer treatment. The company's pipeline includes investigational agents targeting critical signaling pathways in cancer cells.
- Research and Innovation: Verastem dedicates resources to researching and identifying novel targets and therapeutic approaches in oncology.
Leadership and Structure
The company is led by a management team with experience in drug development and commercialization. The organizational structure consists of research, development, clinical, and commercial teams.
Top Products and Market Share
Key Offerings
- Avutometinib: Avutometinib is Verastem's RAF/MEK clamp. Market share is hard to determine due to the development stage of the drug. Key Competitors: Trametinib (Mekinist) by Novartis, Cobimetinib (Cotellic) by Roche, Binimetinib (Mektovi) by Pfizer, Selumetinib by AstraZeneca, Encorafenib (Braftovi) by Pfizer
- Defactinib: Defactinib is a FAK inhibitor used in combination with chemotherapy. Competitors include other chemotherapy regimens, and other companies pursuing FAK inhibition such as KSQ Therapeutics. Market share data is not available due to development stage of drug.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, complex regulatory processes, and intense competition. The oncology segment is driven by the increasing prevalence of cancer and advancements in targeted therapies and immunotherapies.
Positioning
Verastem is focused on targeted therapies for cancer, particularly those addressing unmet medical needs. The company's competitive advantage lies in its innovative pipeline and its focus on specific signaling pathways.
Total Addressable Market (TAM)
The global oncology market is projected to reach hundreds of billions of dollars. Verastem is positioned to capture a share of this market through its pipeline of targeted therapies, focusing on specific cancer subtypes and treatment approaches.
Upturn SWOT Analysis
Strengths
- Proprietary RAF/MEK clamp drug (Avutometinib)
- Experienced Management Team
- Innovative pipeline focused on targeted therapies
- Strong focus on oncology
Weaknesses
- Reliance on clinical trial success
- High R&D costs
- Limited commercial infrastructure
- Dependence on partnerships for development and commercialization
Opportunities
- Expanding indications for existing pipeline products
- Partnering with larger pharmaceutical companies
- Acquiring or licensing new technologies
- Advancing combination therapies
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established pharmaceutical companies
- Patent expirations
Competitors and Market Share
Key Competitors
- NVS
- PFE
- AZN
- ROSY
Competitive Landscape
Verastem faces competition from established pharmaceutical companies with greater resources and broader product portfolios. However, Verastem's targeted therapies and innovative pipeline offer a competitive advantage in specific oncology niches.
Growth Trajectory and Initiatives
Historical Growth: Growth has been dependent on clinical trial results and partnership agreements.
Future Projections: Future growth is contingent on successful clinical trials, regulatory approvals, and commercialization of pipeline products. Analyst estimates vary based on the potential of the company's therapies.
Recent Initiatives: Recent initiatives include advancing clinical trials for avutometinib, seeking regulatory approvals, and exploring partnerships for commercialization.
Summary
Verastem is a development-stage biopharmaceutical company with a focus on targeted cancer therapies, particularly avutometinib. Their success hinges on positive clinical trial outcomes and strategic partnerships. The company faces significant competition and financial challenges, but their innovative pipeline offers potential for future growth. Clinical trial results are of critical importance to Verastem's financial future. It needs to develop more funding options for its long term financial stability.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be made based on individual circumstances and consultation with a qualified financial advisor. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Verastem Inc
Exchange NASDAQ | Headquaters Needham, MA, United States | ||
IPO Launch date 2012-01-27 | President, CEO & Director Mr. Daniel W. Paterson | ||
Sector Healthcare | Industry Biotechnology | Full time employees 78 | Website https://www.verastem.com |
Full time employees 78 | Website https://www.verastem.com | ||
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.